Iridex IRIX
Iridex FY 2022: revenue $57.0M, up 6%; diluted EPS −$0.47
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-007061
- Document
- 10-K
Key figures from this report
These are the numbers Iridex reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$57.0M+6% from $53.9M in FY 202110-K income statement, on EDGAR
- Net income−$7.5MAgainst −$5.2M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$0.47Against −$0.34 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$13.9M−42% from $23.9M in FY 202110-K balance sheet, on EDGAR
- Cash from operations−$9.5M−216% from $8.2M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Nexalin Technology NXL public float $15M, Jun 30, 2025
- Biotricity BTCY public float $13M, Sep 30, 2025
- Beyond Air XAIR public float $16M, Sep 30, 2025
- RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
- Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025
